Concept
Adénosine triphosphate
Personnes associées (33)
Patrick Aebischer
Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Lijing Xin
Lijing Xin is a research staff scientist and 7T MR Operational Manager at the Center for Biomedical Imaging (CIBM), Ecole polytechnique fédérale de Lausanne (EPFL), Switzerland. Her research interests focus on developing cutting-edge magnetic resonance spectroscopy and imaging methods for better understanding the brain function and the pathophysiology of neurological diseases. Her journey on magnetic resonance imaging (MRI) started from her master project during 2002-2005, where she developed a gradient unit with eddy current compensation and a pulse sequence generator for MRI spectrometer, which enhanced her knowledge in MR instrumentation. Later, she obtained her PhD in physics from Ecole polytechnique fédérale de Lausanne (EPFL) in 2010, where she focused on developing various novel 1H and 13C magnetic resonance spectroscopy (MRS) acquisition and quantification methods as well as RF coils on high field preclinical MR scanners. Afterwards, she started working on the clinical MR platforms including both 3 and 7T and continued to improve and develop novel acquisition and quantification methods for 1H, 13C and 31P nuclei. She carries on interdisciplinary collaborations with different partners, particularly with clinical partners where translational strategies are performed to explore the pathophysiology of psychiatric disorders and disease biomarkers for early diagnose and intervention.
John McKinney
Professor John McKinney received his Ph.D. from The Rockefeller University (New York, NY) in 1994 for studies on cell cycle regulation in
Saccharomyces cerevisiae
in the laboratory of Fred Cross. From 1995 to 1998, he was a postdoctoral fellow in the laboratory of William Jacobs at the Albert Einstein College of Medicine (Bronx, NY), where he studied mechanisms of persistence in
Mycobacterium tuberculosis
. In 1999, he returned to Rockefeller University to establish his own laboratory as an Assistant (1999-2004) and then Associate (2004-2007) Professor. In July 2007, the lab relocated to the Global Health Institute in the School of Life Sciences at the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, where McKinney is Professor and Head of the Laboratory of Microbiology and Microsystems (LMIC). Our research focuses on understanding the mechanistic basis of bacterial persistence in the context of host immunity and antimicrobial therapy, using
M. tuberculosis
as a "model" system.